Multicenter Phase III Randomized Study of FOLFIRI Plus Bevacizumab Following or Not by a Maintenance Therapy With Bevacizumab in Patients With Non-Pretreated Metastatic Colorectal Cancer

Trial Profile

Multicenter Phase III Randomized Study of FOLFIRI Plus Bevacizumab Following or Not by a Maintenance Therapy With Bevacizumab in Patients With Non-Pretreated Metastatic Colorectal Cancer

Completed
Phase of Trial: Phase II/III

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms PRODIGE 9
  • Most Recent Events

    • 18 Jan 2018 Primary endpoint (Tumor (disease)-control duration) has not been met, as per the results published in the Journal of Clinical Oncology.
    • 18 Jan 2018 Status changed from active, no longer recruiting to completed, as per the results published in the Journal of Clinical Oncology.
    • 18 Jan 2018 Results published in the Journal of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top